We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




No Benefit for Heparin in the Acute Setting

By HospiMedica International staff writers
Posted on 12 Jan 2012
The use of low-molecular-weight heparin along with graduated compression stockings failed to reduce 30-day all-cause mortality among acutely ill medical patients, according to a new study.

Researchers at University College London (UCL; United Kingdom) and other institutions conducted a placebo-controlled, randomized trial to assess the effect of subcutaneous enoxaparin (40 mg daily) as compared with placebo--both administered to 8,307 patients who were wearing elastic stockings with graduated compression--on the rate of death from any cause at 30 days among hospitalized, acutely ill patients at participating sites in China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia. More...
Inclusion criteria were age of at least 40 years, hospitalization for acute decompensated heart failure (HF), and severe systemic infection with at least one risk factor for venous thromboembolism, or active cancer.

The results showed that the rate of death from any cause at day 30 was 4.9% in the enoxaparin group, as compared with 4.8% in the placebo group; two-week all-cause mortality was similar in the two groups, at 2.9% in each, and three-month all-cause mortality was also similar, with a hazard rate of 8.4% for patients receiving thromboprophylaxis and 8.6% for those receiving placebo. The rate of major bleeding was 0.4% in the enoxaparin group and 0.3% in the placebo group. Analysis revealed that pulmonary failure was the most common cause of death at 30 days; other causes included active cancer, impaired kidney function, two or more coexisting acute illnesses, and chronic pulmonary disease. The study was published in the December 29, 2011, issue of the New England Journal of Medicine (NEJM).

“While thromboprophylaxis in surgical patients has been shown to decrease the rate of lethal pulmonary embolism, acutely ill medical patients may be at risk for death from many causes other than pulmonary embolism, thus diminishing the ability of pharmacologic prophylaxis to improve the overall clinical outcome,” concluded lead author Ajay Kakkar, MBBS, PhD, of UCL, and colleagues. “Another possible reason for the lack of a benefit could be that rates of pulmonary embolism have been reported to be lower in Asia than in Western countries.”

Heparin is a highly sulfated glycosaminoglycan, widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Although it is used principally in medicine for anticoagulation, its true physiological role in the body remains unclear, because blood anticoagulation is achieved mostly by heparan sulfate proteoglycans. It has been proposed that, rather than anticoagulation, the main purpose of heparin is defense at such sites against invading bacteria and other foreign materials.

Related Links:
University College London



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.